主要心血管疾病的患者成本:国际文献综述。

Q4 Medicine Sovremennaya Revmatologiya Pub Date : 2016-09-21 eCollection Date: 2016-01-01 DOI:10.2147/CEOR.S89331
Gina Nicholson, Shravanthi R Gandra, Ronald J Halbert, Akshara Richhariya, Robert J Nordyke
{"title":"主要心血管疾病的患者成本:国际文献综述。","authors":"Gina Nicholson, Shravanthi R Gandra, Ronald J Halbert, Akshara Richhariya, Robert J Nordyke","doi":"10.2147/CEOR.S89331","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Robust cost estimates of cardiovascular (CV) events are required for assessing health care interventions aimed at reducing the economic burden of major adverse CV events. This review synthesizes international cost estimates of CV events.</p><p><strong>Methods: </strong>MEDLINE database was searched electronically for English language studies published during 2007-2012, with cost estimates for CV events of interest - unstable angina, myocardial infarction, heart failure, stroke, and CV revascularization. Included studies provided at least one estimate of patient-level direct costs in adults for any identified country. Information on study characteristics and cost estimates were collected. All costs were adjusted for inflation to 2013 values.</p><p><strong>Results: </strong>Across the 114 studies included, the average cost was US $6,466 for unstable angina, $11,664 for acute myocardial infarction, $11,686 for acute heart failure, $11,635 for acute ischemic stroke, $37,611 for coronary artery bypass graft, and $13,501 for percutaneous coronary intervention. The ranges for cost estimates varied widely across countries with US cost estimate being at least twice as high as European Union costs for some conditions. Few studies were found on populations outside the US and European Union.</p><p><strong>Conclusion: </strong>This review showed wide variation in the cost of CV events within and across countries, while showcasing the continuing economic burden of CV disease. The variability in costs was primarily attributable to differences in study population, costing methodologies, and reporting differences. Reliable cost estimates for assessing economic value of interventions in CV disease are needed.</p>","PeriodicalId":36215,"journal":{"name":"Sovremennaya Revmatologiya","volume":"2 1","pages":"495-506"},"PeriodicalIF":0.0000,"publicationDate":"2016-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036826/pdf/","citationCount":"0","resultStr":"{\"title\":\"Patient-level costs of major cardiovascular conditions: a review of the international literature.\",\"authors\":\"Gina Nicholson, Shravanthi R Gandra, Ronald J Halbert, Akshara Richhariya, Robert J Nordyke\",\"doi\":\"10.2147/CEOR.S89331\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Robust cost estimates of cardiovascular (CV) events are required for assessing health care interventions aimed at reducing the economic burden of major adverse CV events. This review synthesizes international cost estimates of CV events.</p><p><strong>Methods: </strong>MEDLINE database was searched electronically for English language studies published during 2007-2012, with cost estimates for CV events of interest - unstable angina, myocardial infarction, heart failure, stroke, and CV revascularization. Included studies provided at least one estimate of patient-level direct costs in adults for any identified country. Information on study characteristics and cost estimates were collected. All costs were adjusted for inflation to 2013 values.</p><p><strong>Results: </strong>Across the 114 studies included, the average cost was US $6,466 for unstable angina, $11,664 for acute myocardial infarction, $11,686 for acute heart failure, $11,635 for acute ischemic stroke, $37,611 for coronary artery bypass graft, and $13,501 for percutaneous coronary intervention. The ranges for cost estimates varied widely across countries with US cost estimate being at least twice as high as European Union costs for some conditions. Few studies were found on populations outside the US and European Union.</p><p><strong>Conclusion: </strong>This review showed wide variation in the cost of CV events within and across countries, while showcasing the continuing economic burden of CV disease. The variability in costs was primarily attributable to differences in study population, costing methodologies, and reporting differences. Reliable cost estimates for assessing economic value of interventions in CV disease are needed.</p>\",\"PeriodicalId\":36215,\"journal\":{\"name\":\"Sovremennaya Revmatologiya\",\"volume\":\"2 1\",\"pages\":\"495-506\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-09-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036826/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Sovremennaya Revmatologiya\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/CEOR.S89331\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2016/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sovremennaya Revmatologiya","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/CEOR.S89331","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2016/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

目的:需要对心血管(CV)事件进行可靠的成本估算,以评估旨在减轻重大不良 CV 事件经济负担的医疗干预措施。本综述综合了国际上对心血管事件的成本估算:通过电子方式在 MEDLINE 数据库中搜索了 2007-2012 年间发表的英文研究,这些研究对相关的 CV 事件(不稳定型心绞痛、心肌梗死、心力衰竭、中风和 CV 血管再通)进行了成本估算。所纳入的研究至少提供了一项对任何已确定国家的成人患者层面直接成本的估算。收集了有关研究特征和成本估算的信息。所有成本均根据通货膨胀率调整为 2013 年的数值:在纳入的 114 项研究中,不稳定型心绞痛的平均费用为 6466 美元,急性心肌梗死为 11664 美元,急性心力衰竭为 11686 美元,急性缺血性中风为 11635 美元,冠状动脉搭桥术为 37611 美元,经皮冠状动脉介入治疗为 13501 美元。不同国家的成本估算范围差异很大,美国某些病症的成本估算至少是欧盟的两倍。针对美国和欧盟以外人群的研究很少:本综述显示,冠心病事件的成本在国家内部和国家之间存在很大差异,同时显示了冠心病带来的持续经济负担。成本差异主要归因于研究人群、成本计算方法和报告差异。需要可靠的成本估算来评估冠心病干预措施的经济价值。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Patient-level costs of major cardiovascular conditions: a review of the international literature.

Objective: Robust cost estimates of cardiovascular (CV) events are required for assessing health care interventions aimed at reducing the economic burden of major adverse CV events. This review synthesizes international cost estimates of CV events.

Methods: MEDLINE database was searched electronically for English language studies published during 2007-2012, with cost estimates for CV events of interest - unstable angina, myocardial infarction, heart failure, stroke, and CV revascularization. Included studies provided at least one estimate of patient-level direct costs in adults for any identified country. Information on study characteristics and cost estimates were collected. All costs were adjusted for inflation to 2013 values.

Results: Across the 114 studies included, the average cost was US $6,466 for unstable angina, $11,664 for acute myocardial infarction, $11,686 for acute heart failure, $11,635 for acute ischemic stroke, $37,611 for coronary artery bypass graft, and $13,501 for percutaneous coronary intervention. The ranges for cost estimates varied widely across countries with US cost estimate being at least twice as high as European Union costs for some conditions. Few studies were found on populations outside the US and European Union.

Conclusion: This review showed wide variation in the cost of CV events within and across countries, while showcasing the continuing economic burden of CV disease. The variability in costs was primarily attributable to differences in study population, costing methodologies, and reporting differences. Reliable cost estimates for assessing economic value of interventions in CV disease are needed.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Sovremennaya Revmatologiya
Sovremennaya Revmatologiya Medicine-Pharmacology (medical)
CiteScore
0.70
自引率
0.00%
发文量
82
审稿时长
5 weeks
期刊最新文献
Роль витаминов-антиоксидантов в этиологии ревматоидного артрита Влияние тофацитиниба на показатели функции и качества жизни у больных ревматоидным артритом, резистентных к синтетическим и биологическим базисным противовоспалительным препаратам, в реальной клинической практике (результаты многоцентрового наблюдательного исследования) Остеоартрит и возраст. Роль старения в этиологии и патогенезе заболевания Применение тофацитиниба для лечения больных ревматоидным артритом, резистентных к синтетическим и биологическим базисным противовоспалительным препаратам, в реальной клинической практике ( результаты многоцентрового наблюдательного исследования) Экономические аспекты осложненного остеопороза: стоимость лечения в течение первого года после перелома
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1